Mounjaro Price Increase: Your Alternatives and What They Actually Cost

What the price increase actually changed, and what it didn't

The September 2025 Eli Lilly list-price revision affected every private provider selling Mounjaro in the UK, because they all source from the same licensed UK supply chain. That means a lower quote from one pharmacy doesn't reflect cheaper medicine, it may reflect a lower-dose pen, a slimmer service, or costs that surface later. Before concluding that Mounjaro has become unaffordable, it's worth checking exactly which dose the quoted price covers. The 2.5mg and 5mg pens carry lower price points than higher doses; the picture for the starter dose looks quite different from the headline figures for 12.5mg or 15mg.

You can read a detailed breakdown of what drove the change (and what providers can and cannot absorb) on our Mounjaro UK price increase overview. The short version: the medicine's wholesale cost rose; the clinical infrastructure around it did not get cheaper either.

One practical habit worth building now: before committing to any provider, spend thirty seconds on the GPhC pharmacy register and confirm their registration number is listed. It takes less time than reading this sentence twice, and it is the fastest filter available for separating regulated pharmacies from unregistered sellers.

The real alternatives when Mounjaro's cost rises

There are three plausible paths for someone reassessing after the price increase. First, continue Mounjaro with a provider whose all-in pricing is transparent, understanding what the number actually includes before assuming a lower headline elsewhere is a genuine saving. Second, discuss switching to Wegovy (semaglutide 2.4mg) with a prescriber. Wegovy is a once-weekly injection licensed for the same weight-management indication, with a different cost structure. In the STEP 1 trial it produced around 15% average weight reduction over 68 weeks, as published in the New England Journal of Medicine; SURMOUNT-1 figures for tirzepatide ran higher, and a 2025 head-to-head trial confirmed tirzepatide produced greater average loss, but the clinical picture is individual. Third, explore what a clinically appropriate alternative to Mounjaro might look like for your specific situation, which is a conversation for a prescriber, not a webpage.

Switching medicines mid-treatment is not something to do unilaterally. Dose, timing and transition steps all matter. Our treatment overview explains the full range of options available through nume.

What headline prices typically leave out, and what nume's transparent price includes

A quoted monthly price for Mounjaro or Wegovy sometimes covers only the pen. Consultation fees, prescription charges, delivery costs and ongoing clinical review can each add to the real total. When comparing, the relevant number is the all-in cost: medicine, clinical review, prescription, delivery and aftercare access combined. Some providers charge separately for each; others bundle selectively.

At nume, one price covers the consultation, the prescription, the medicine, free next-working-day tracked delivery and seven-day aftercare, no line items, no recurring subscription charges, no auto-renewal. We don't run discount codes or promotional offers on prescription medicines, and there's a straightforward reason for that: a POM is not a retail product to discount. Every repeat order is clinically re-reviewed before it leaves our GPhC-registered pharmacy.

We are not the cheapest option in the market. That is a deliberate choice. What the cheapest listing often doesn't include is worth reading before making cost your deciding factor. For dose-specific pricing context, the 5mg price picture and the broader Mounjaro cost guide cover the current landscape in more detail.

Why price is the wrong measure for a prescription medicine

The MHRA has warned publicly about counterfeit weight-loss pens, fake tirzepatide pens seized from an illicit UK manufacturing site as recently as October 2025, and around 20 million doses of illegally traded weight-loss medicines intercepted in 2025 alone, with an estimated street value of around £45 million. Fake pens have in some cases contained insulin. The supply chain matters in a way it simply doesn't for paracetamol.

A clinically supervised, genuine-supply-chain service is the right benchmark for comparing providers, not the monthly figure taken in isolation. NICE's appraisal of tirzepatide (TA1026) and NHS England's guidance on weight-management injections both make clear that these medicines sit within a framework of clinical oversight for good reason. The prescriber reviewing your case (at nume, always a named GPhC-registered prescriber, every time) is part of what you are paying for. That review is what separates a legitimate private prescription from a parcel that arrives from an unverified source. Our clinical team and the prescribers listed on our clinical profile page are accountable in a way no anonymous online seller can be.